Literature DB >> 11096701

Ischemic Stroke Prevention.

.   

Abstract

More than 700,000 strokes occur annually in the United States--one every 40 to 50 seconds. Although stroke is one of the nation's most expensive diseases to treat, costing $41 billion per year, most strokes (perhaps as many as two thirds) are preventable. Twenty percent of the United States population will have 80% of all strokes; this estimate is based on five established, major risk factors for stroke: hypertension, diabetes mellitus, cigarette smoking, hyperlipidemia, and heart disease. Therefore, stroke is not random but is generally predictable. It is an ideal target for effective prevention strategies that are simple and inexpensive. Ischemic stroke prevention has been shown to be effective in several scenarios: primary prevention, prevention after a transient ischemic attack (TIA), and secondary prevention. Dietary, lifestyle, and risk factor modification; use of aspirin, ticlopidine, clopidogrel, and warfarin; and carotid endarterectomy all have a role in stroke prevention in selected persons. Emerging therapies include the use of vitamins, cerebral arterial angioplasty, and stenting. Annual risk assessment, screening, and intervention should be part of a concerted national effort to reduce the incidence of the third leading cause of death and the number one cause of adult disability in the United States.

Entities:  

Year:  1999        PMID: 11096701     DOI: 10.1007/s11940-999-0011-y

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  47 in total

Review 1.  Decision analytic and cost-effectiveness issues concerning anticoagulant prophylaxis in heart disease.

Authors:  M H Eckman; H J Levine; S G Pauker
Journal:  Chest       Date:  1992-10       Impact factor: 9.410

2.  The protective effect of moderate alcohol consumption on ischemic stroke.

Authors:  R L Sacco; M Elkind; B Boden-Albala; I F Lin; D E Kargman; W A Hauser; S Shea; M C Paik
Journal:  JAMA       Date:  1999-01-06       Impact factor: 56.272

3.  American Heart Association Prevention Conference. IV. Prevention and Rehabilitation of Stroke. Risk factors.

Authors:  R L Sacco; E J Benjamin; J P Broderick; M Dyken; J D Easton; W M Feinberg; L B Goldstein; P B Gorelick; G Howard; S J Kittner; T A Manolio; J P Whisnant; P A Wolf
Journal:  Stroke       Date:  1997-07       Impact factor: 7.914

4.  Variation in carotid endarterectomy mortality in the Medicare population: trial hospitals, volume, and patient characteristics.

Authors:  D E Wennberg; F L Lucas; J D Birkmeyer; C E Bredenberg; E S Fisher
Journal:  JAMA       Date:  1998 Apr 22-29       Impact factor: 56.272

Review 5.  Primary prevention of stroke.

Authors:  L L Bronner; D S Kanter; J E Manson
Journal:  N Engl J Med       Date:  1995-11-23       Impact factor: 91.245

6.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

7.  Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials.

Authors:  H C Bucher; L E Griffith; G H Guyatt
Journal:  Ann Intern Med       Date:  1998-01-15       Impact factor: 25.391

8.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

9.  Risk of stroke during long-term anticoagulant therapy in patients after myocardial infarction.

Authors:  A J Azar; P J Koudstaal; A R Wintzen; P F van Bergen; J J Jonker; J W Deckers
Journal:  Ann Neurol       Date:  1996-03       Impact factor: 10.422

10.  Medical treatment for stroke prevention.

Authors:  D B Matchar; D C McCrory; H J Barnett; J R Feussner
Journal:  Ann Intern Med       Date:  1994-07-01       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.